#Pendopharm
LightNews LightNews
oags.bsky.social
Attn. General Surgeons, Fellows, Residents, PAs - 2025 OAGS Surgical Symposium, Nov.8. Sponsored Breakfast talk ft. Dr. Jason Reinglas re. Mgmt of IBD. Limit: 30ppl. #OAGS2025 #TorontoOntario🇨🇦. @_Pharmascience_ #Pendopharm #colorectal #generalsurgery #meded Details: rebrand.ly/e4ti4n7
November 3, 2025 at 8:47 PM
angioedemanews.bsky.social
Pendopharm has secured exclusive rights to bring sebetralstat to Canada. An investigational, on-demand hereditary angioedema (HAE) treatment developed by KalVista, sebetralstat is designed to provide rapid relief from swelling attacks, offering a potential new standard in HAE care.
July 18, 2025 at 2:02 PM
nasdaq.activitypub.awakari.com.ap.brid.gy
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada -Sebetralstat has potential to become first oral on-demand treatment for HAE...

#Business #Wire #News #Releases #PMN #Press #Releases #BW

Origin | Interest | Match
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
-Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada-
financialpost.com
June 26, 2025 at 11:49 AM
stocktitan.net
#KALV KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

https://www.stocktitan.net/news/KALV/kal-vista-pharmaceuticals-enters-into-licensing-agreement-with-k44gupoonjw5.html
KalVista's Breakthrough Oral HAE Drug Sebetralstat Secures Canadian Partnership: First-Ever Pill Treatment
KalVista partners with Pendopharm to bring first-ever oral treatment for hereditary angioedema to Canadian market. Discover expansion strategy details.
www.stocktitan.net
June 26, 2025 at 11:00 AM